Income Statement
BOLT BIOTHERAPEUTICS, INC.
BOLT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
7.70 | 7.69 | 7.88 | 5.73 | 1.30 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
7.70 | 7.69 | 7.88 | 5.73 | 1.30 |
|
Operating Expenses
|
43.81 | 80.74 | 84.07 | 96.05 | 94.05 |
|
Research & Development
|
28.53 | 57.47 | 61.54 | 73.12 | 75.66 |
|
Selling, General & Administrative
|
13.80 | 18.46 | 22.53 | 22.93 | 18.39 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-36.11 | -73.05 | -76.20 | -90.32 | -92.75 |
|
Non-Operating Income
|
2.74 | 9.93 | 7.00 | 2.22 | -5.80 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-33.38 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-33.38 | -63.12 | -69.20 | -88.10 | -98.59 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-34.82 | -71.27 | -74.34 | -88.66 | -91.56 |
|
Earnings Per Share (Basic)
|
-17.85 | -1.65 | -1.83 | -2.36 | - |
|
Diluted EPS
|
-17.85 | -1.65 | -1.83 | -2.36 | - |
|
Weighted Average Shares
|
1.87 | 38.18 | 37.81 | 37.36 | 33.22 |
|
Diluted Weighted Avg Shares
|
1.87 | 38.18 | 37.81 | 37.36 | - |
|
Comprehensive Income
|
-33.49 | -63.06 | -68.24 | -88.70 | -98.91 |